Ziprasidone hydrochloride monohydrate

A full antagonist of D2 and 5-HT2A receptors with Ki of 6.8 and 0.6 nM, respectively; also is a partial agonist of 5-HT1A, and a partial antagonist of 5-HT2C and 5-HT1D receptors; exhibits potent antipsychotic activity in vivo.Schizophrenia Approved (In Vitro) :Ziprasidone hydrochloride monohydrate (0-500 nM, 150 seconds) blocks wild-type hERG current. (In Vivo) :Ziprasidone hydrochloride monohydrate (oral gavage; 20 mg/kg; once daily; 7 weeks) results in weight loss, low level physical activity, high resting energy expenditure and greater capacity for thermogenesis when subjected to cold.